These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 26959061)

  • 1. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
    Carraro E; Trevisi E; Martinuzzi A
    Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.
    Ravenni R; De Grandis D; Mazza A
    Neurol Sci; 2013 Jul; 34(7):1043-8. PubMed ID: 23576131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A (Dysport®): in dystonias and focal spasticity.
    Keam SJ; Muir VJ; Deeks ED
    Drugs; 2011 May; 71(8):1043-58. PubMed ID: 21668041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical differences between botulinum neurotoxin type A and B.
    Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
    Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
    Matarasso A; Shafer D
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The setting of a botulinum toxin treatment service.
    Cavallini M
    Neurol Sci; 2014 May; 35 Suppl 1():49-50. PubMed ID: 24867836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
    Kazerooni R; Broadhead C
    Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
    Jost WH; Blümel J; Grafe S
    Drugs; 2007; 67(5):669-83. PubMed ID: 17385940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
    Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.